Full Press Release Details
Announces Warrants Exchange Listing Transfer to Nasdaq
to be NSPRW and NSPRZ
Aviv, Israel- May 27, 2021 - InspireMD,
Inc. (Nasdaq: NSPR), developer
of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD),
today announced the Company's warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing
on The Nasdaq Capital Market ("Nasdaq"). Trading is expected to begin on June 8, 2021, under the symbols NSPRW and NSPRZ
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing
outstanding acute results and durable, stroke-free, long-term outcomes.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject
to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing
and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory
approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies,
(v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors
for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our
efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x)
legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers
for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the
future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple
foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens
and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.